Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Jul 13, 2020

SELL
$0.56 - $1.41 $19,460 - $48,997
-34,750 Closed
0 $0
Q1 2020

Apr 17, 2020

BUY
$0.51 - $1.08 $10,837 - $22,950
21,250 Added 157.41%
34,750 $25,000
Q4 2019

Feb 04, 2020

BUY
$0.53 - $1.59 $7,155 - $21,465
13,500 New
13,500 $12,000

Others Institutions Holding OTLK

About Outlook Therapeutics, Inc.


  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $1.72B
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track Dfpg Investments, LLC Portfolio

Follow Dfpg Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dfpg Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dfpg Investments, LLC with notifications on news.